



Grape King Bio (1707 TT) Investor Presentation

November 2022

Confidential



Disclaimer


- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs. losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.





Company Profile

Confidentia



Company Overview: Three core business units



1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM

Locus of all key ingredient design, formulation, and production for the whole Group.



2. Pro-Partner (60%-own) **Taiwan direct selling distribution**


A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.




3. Grape King Shanghai (100%-own) China OEM & ODM

Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.










■ Grape King Taiwan ■ Pro-Partner ■ Grape King Shanghai

Consistent Organic Revenue Growth





ODM Key Growth Driver

Grape King Taiwan ODM Sales



Botanical Drug Submitted to USFDA

- Antrodia is a traditional Chinese mushroom unique to Taiwan, know for its liver protection and cancers fighting benefits.
- Grape King Bio has been researching Antrodia for more than 20 years, with various health food supplements already being sold in Taiwan.
- Our new botanical drug "GKAC" (based on Antrodia camphorata mycelium, 100% exclusive to GKB) has been submitted to the US Food and Drug Administration (USFDA) for a Phase II clinical trial review (IND) for nonalcoholic steatohepatitis (NASH) in humans.
- Key components were found in clinical pre-experiments, which can significantly improve liver function in patients with non-alcoholic fatty liver disease (NAFLD). This disease is the initial stage of the development of liver disease such as steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (i.e. liver cancer).
- If our botanical is drug is passed by USFDA, it will be the first drug of its kind to treat non-alcoholic fatty liver disease (NAFLD).

Going Global

Pro-Partner

- Pro-Partner will be heading to Malaysia as part of their expansion to overseas markets
- Malaysia has a well regulated and accepting MLM market
- 5 products have been submitted for MAL certification
- Sales are expected to start at the end of 2023

葡衆企業 PRO-PARTNER

Taiwan Grape King

- Working with multinational clients we have been developing new products for ASEAN markets
- We are in discussions with European clients to supply probiotic products
- GKB (Malaysia) established in 2018, selling products to the Malaysian and neighboring countries.







Our Sustainability Progress

2021



PURPOSE-LED BRAND

20%

of our revenues are aligned with United Nation's (UN) Sustainable **Development Goals (SDGs)**



CLEANER PLANET

475kg

of CO2e of carbon emission reduced in 2021



FAIRER SOCIETY

815hrs

service hours were invested in community investment projects in 2021



STRONGER STEWARDSHIP

33%

Of Board independence is expected in the coming Board election





Adopted SASB indicators for ESG communications with investors. We have also added TCFD



Of renewable energy usage by 2035 (15% by 2030)

NT\$1.38mn

invested in employee health management and health promotion

42%

of female board members expected in the coming Board election, higher than TWSE average of 13.4%

Delivering on ESG Scores

TWSE CG Score S&P Global Sustainalytics MSCI FTSE Russell ISS ESG 風險評分 ‡ ESG評級 * ESG 評級 ÷ ESG評級 = ESG評分 章 台灣公司治理評鑑 證券代號/公司名稱 = (100-0, 0分最佳) ? (AAA-CCC, AAA最佳) ? (0-5, 5級最佳) ? (A-D, A級最佳) ? (0-100, 100分最佳) ? (前5%最佳) ? 1707 葡萄王 19.11 3.5 前5% Not covered Not covered

Grape King Bio 1707

Started data input on

10/2021

Top 5%

Published by IR Platform website - Sept 2022



ESG Risk Rating of 19.11, ranked no. 5 in Global Personal Product companies



Top 35% of all global companies, and the top scoring supplier of our ODM client



Top 5% among all TWSE companies in 2020 Corporate Governance Assessment





Our Core Competence



We are industry leader

- ✓ We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements. We command No. 1 position in probiotics and medicinal mushrooms supplements with 31% and 45% market share, respectively in 2020.
- ✓ We operate the second largest direct-selling company Pro-Partner in Taiwan (2021 market share: 8.3%).
- ✓ Approximately 50 OEM/raw materials customers in Taiwan.



Strong R&D capabilities

- ✓ We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- ✓ Our expertise in raw materials allow us to develop health supplements serving different benefits. Therefore, many of our products are TFDA approved for different health benefits.
- ✓ We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



Solid growth with sustainable payout ratio

- ✓ We have delivered a solid earnings during 2008-2021 (CAGR of 19%/average ROE 25%).
- ✓ We have maintained more than 60% dividend payout in the past five years.
- ✓ On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.

Our Growth Strategies for Three Key Businesses





Key Objectives

Grape King Taiwan

- Market share gain
- Expanding through new adjacencies
- Accelerate overseas ODM & raw materials businesses

Levers

- Market share gain through products upgrade and deeper channels penetration
- Business expansion through penetrating new product categories
- ✓ Continue to promote Grape King's raw material and R&D capabilities in probiotics and medicinal mushrooms.

Pro-Partner

- · Unlock growth ceiling
- · Improving demand forecast, sales visibility, and products time to market
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- Focus on growing younger members.
- Duplicate Taiwan success in new geographies

Grape King Shanghai


- · Clients diversification
- Prepping for the probiotics boom
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- Develop non-direct/WeChat customers
- ✓ Capture more business opportunities through local strategic partnerships and alliances





Competitive Strengths - Strong Products Capabilities

We acquired more than 186 patents and published over 84 research papers. Also, we acquired more than 10 TFDA Health Food certifications on our products.



2015~2022 : 21 countries, 198 awards



Our Sustainability Progress

2021





PURPOSE-LED BRAND

72%

of our revenues are aligned with United Nation's (UN) Sustainable **Development Goals (SDGs)**



Adopted SASB indicators for ESG communications with investors. We have also added TCFD



CLEANER PLANET

475kg

of CO2e of carbon emission reduced in 2021



Of renewable energy usage by 2035 (15% by 2030)



FAIRER SOCIETY

815hrs

service hours were invested in community investment projects in 2021

NT\$1.38mn

invested in employee health management and health promotion



STRONGER STEWARDSHIP

33%

Of Board independence is expected in the coming Board election

42%

of female board members expected in the coming Board election, higher than TWSE average of 13.4%

Third-Party ESG Credentials



Top 5% among all TWSE companies in 2020 Corporate Governance Assessment



ESG Risk Rating of 20.78, ranked no. 5 in Global Personal **Product companies**



Top 35% of all global companies, and the top scoring supplier of our **ODM** client






Financial Performance

Confidential

Revenue Breakdown (1H22 vs. 1H21)





1H22 NET PROFIT +11.2% YoY

25%

1.Grape King Taiwan NT\$ 482mn (+ 7% YoY)


Thanks to strong sales of our own brand products as well as higher ODM revenues. However, higher opex was incurred due to beverage products (Kombucha and POWERBomb).

2.Pro-Partner NT\$ 4.08bn (+ 15% YoY)

The outbreak of the pandemic in Taiwan has helped to drive Pro-Partner's sales with the increase in demand for immune boosting products.



China sales were severely impacted by the lockdowns they have experienced in Shanghai and other cities.





NT\$

621mn

Five-Year Income Statement

(NT\$ m)	2017	2018	2019	2020	2021	3Q22			YoY	(%)		
(1412 111)	2017	2010	2017	2020	2021	30(22	2017	2018	2019	2020	2021	1H22
Revenue	9,388	9,183	9,239	9,168	9,798	7,267	2.2	(2.2)	0.6	(0.8)	6.9	6.7
Gross Profit	7,865	7,329	7,566	7,537	7,855	5,910	(0.7)	(6.8)	3.2	(0.4)	4.2	10.4
Operating Expenses	(5,610)	(4,979)	(5,231)	(5,232)	(5,543)	(4,181)	(1.3)	(11.2)	5.0	0.0	5.9	9.5
Operating Profit	2,254	2,350	2,335	2,305	2,312	1,729	0.9	4.2	(0.6)	(1.3)	0.3	12.9
Non Operating Income/(Loss)	151	77	105	73	103	92	92.6	(49.2)	36.8	(30.2)	41.1	43.2
Pretax Income	2,405	2,427	2,440	2,378	2,415	1,821	4.0	0.9	0.6	(2.5)	1.6	14.1
Tax Expenses	(471)	(537)	(502)	(483)	(467)	(348)	10.6	14.0	(6.5)	(3.7)	(3.3)	17.5
Minority Interest	(583)	(595)	(630)	(623)	(647)	(488)	(1.3)	2.1	5.9	(1.1)	3.9	18.0
Net income to Parent	1,352	1,295	1,309	1,272	1,300	985	4.3	(4.2)	1.1	(2.8)	2.2	11.2
Basic EPS (NT\$)	10.03	9.57	9.63	9.34	8.81	6.65	2.1	(4.6)	0.6	(3.0)	(5.7)	10.3
Key Financial Ratios (%)												
Gross Margin	83.8	79.8	81.9	82.2	80.2	81.3						
Operating Expense Ratio	59.8	54.2	56.6	57.1	56.6	57.5						
Operating Margin	24.0	25.6	25.3	25.1	23.6	23.8						
Effective Tax Rate	19.6	22.1	20.6	20.3	19.3	19.1						
Net Margin	14.4	14.1	14.2	13.9	19.9	20.3						

Five-Year Income Statement

	1
1	$\gamma \gamma$
	$\angle \angle$
-	

(NT\$ m)	2017	2018	2019	2020	2021 3Q22	YoY (%)						
(1415 111)	2017	2010	2017	2020	2021	2021 0022	2017	2018	2019	2020	2021	1H22
Total Assets	9,892	10,648	11,359	13,104	14,061	13,695	3.6	7.6	6.7	15.4	7.3	3.4
Cash	1,920	2,050	2,146	2,927	3,635	3,249	1.1	6.8	4.7	36.4	24.2	(9.6)
AR & NR	160	171	202	202	301	339	(21.5)	6.8	18.0	(0.2)	49.0	4.5
Inventories	492	563	546	689	719	732	13.1	14.4	(2.9)	26.2	4.4	(4.5)
Fixed Assets	6,355	5,927	6,454	7,308	7,208	7,224	4.5	(6.7)	8.9	13.2	(1.4)	(0.4)
Total Liabilities	3,564	3,715	3,888	5,126	3,631	3,243	(5.4)	4.2	4.7	31.8	(29.2)	27.9
AP & NP	323	262	223	255	269	324	63.2	(18.9)	(15.1)	14.7	5.5	12.8
Total Borrowing	1,022	1,119	1,177	1,921	94	0	(15.2)	9.5	5.2	63.3	(95.1)	(100.0)
Total Equity	6,328	6,933	7,471	7,978	10,429	10,452	9.4	9.6	7.8	6.8	30.7	(5.1)
Total Financial Ratios (%)												
A/R Turnover Days	7.0	6.5	7.3	7.9	13.7	12.2						
Inventory Turnover Days	109.5	102.4	119.3	136.4	158.7	150.2						
A/P Turnover Days	61.6	56.8	52.2	52.7	56.7	59.8						
Cash Conversion	54.9	52.1	74.4	91.6	115.7	102.6						
ROE (%)	27.0	23.7	22.0	19.9	13.6	18.8						
ROA (%)	13.9	12.6	11.9	10.4	10.3	14.2						
Net debt (cash)/Equity %	(14.2)	(13.4)	(13.0)	(12.6)	(32.4)	(31.1)						



(NT\$ m)	2015	2016	2017	2018	2019	2020	2021
Net Profit	1,052	1,297	1,352	1,295	1,309	1,272	1,300
Cash Dividend	730	862	903	883	884	948	904
DPS (NT\$)	5.6	6.4	6.7	6.5	6.5	6.4	6.1
Payout Ratio	69.4%	65.2%	66.6%	67.9%	67.4%	68.5%	69.2%
Cash Yield	2.6%	3.2%	2.9%	3.0%	3.3%	3.8%	3.9%
Capex	2,635	736	772	1,116	630	1,214	1,481

Notes:

- 1. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.
- 2. The capex for 2021 is mainly used for building of the new Pingzhen plant for new production facilities.
- 3. 2021 cash yield is calculated based on Grape King's 2021/6/11 closing share price NT\$155.

Production

Capsules

PKL

PIC/S

Fine Granule

Liquids-Big CC

Production

Lactobacilli

Mushroom

PKL Liquids

Liquids-Small CC 1 M bottles

Our Capacity and Expansion Plan



Grape King Specialist Fermentation & Manufacturing Site*

Monthly Capacity

Capacity

7 M capsules

2 M pack

4.2 M bottles

1 M bottles

1.4 M bottles

0.8 M packs

2021

25 tons

161.5 tons

80 tons

7 M capsules

2 M pack

4.2 M bottles

1.4 M bottles

0.8 M packs

2020

25 tons

161.5 tons

80 tons







Production	Monthly Capacity				
Line	2020	2021			
Liquids(Glass)	18 M bottles	18 M bottles			
Liquids (Retort Pouch)	3 M packs	3 M packs			
Powder	15 M pack	15 M pack			
Capsules	7 M capsules	7 M capsules			
Troches	63 M capsules	63 M capsules			

Grape King Bio-Tech Headquarter



I TOUUCTION	التستخيف المستحدث	C1.		
Line	2020	2021	Start	
Capsules	13M capsules	13M capsules	-	
ine Granule	15M pack	15M pack	-	
owder	1.8M packs	1.8M packs	-	

Grape King Bio-Tech Research Institute



Production	Capacity			
Line	2020	2021		
Lactobacilli	40 tons	40 tons		
Mushroom	60 tons	60 tons		

^{**}Monthly capacity =30,000 packs/hr x 12 hrs/day x 20 working days/month















3129



^{*}Our Specialist Fermentation & Manufacturing Site (Zhongli plant) will relocated to Pinzhen Industrial Zone due to city development plan, expansion for PKL and different forms production line. The new plant construction is schedule to begin in the second half of 2020 with production expected to start in 2023. The relocation won't impact our operating and we expect that once the new facility is fully completed and 100% utilized, it is able to contribute additional NT\$10bn in revenue for Grape King.





Industry Trends

Confidential




Taiwan Health Food Industry

Taiwanese Takes Nutraceuticals Post-Pandemic are 4 Times Greater than Americans

- The annual consumptions of health food in Taipei Metropolis is TWD 21,000 (USD 700)/people in average, which is 3.7X comparing to the spending of TWD 4,400 (USD 147) in the US.
- Statistics showed that 74% of Taipei Metropolis people takes Nutraceuticals, comparing to 80% of people in the US.

Taipei Metropolis					
1	Vitamin B Group	42%			
2	Probiotic	41%			
3	Lutein	32%			
4	Vitamin C	24%			
5	Fish Oil	19%			
6	Multivitamins	18%			
7	Vitamin D	13%			
8	Chicken Essence	7%			
9	Lactic Acid Bacteria	7%			
10	Collagen	5%			
11	Turmeric	5%			



USA					
1	Vitamin D	73%			
2	Magnesium	52%			
3	Omega-3	51%			
4	Q10	45%			
5	Multivitamins	43%			
6	Vitamin C	42%			
7	Probiotic	39%			
8	Zinc	37%			
9	Turmeric	36%			
10	Vitamin B12	33%			
11	Vitamin B Group	33%			

Source: Learneating, Taiwan



China's Health Food Industry Grew 6.4% CAGR Between 2016-2026


Overall, there is no brand that can monopolize the market in China's health supplement market. In 2021, the top 15 brands only occupied 32.8% of the market share, and no brand can own more than 10% of the market.

China Health Supplements Market, 2016-2026E CAGR 6.4% 12% 10% 2017 2018 2020 2021 2022E 2023E 2024E Market size (RMB bn) ─■─YoY Growth (RHS)

Source: Euromonitor

China Direct Selling Continues to Play an Important Role

Direct selling remains as an important distribution channel in China despite that the e-commerce become popular over the recent years.




Source: Euromonitor

Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.



China's Aging Society Reached 7.18 Trillions Population


According to iiMedia Research, the market size of China's health supplements for seniors accounting for more than 50% of the overall market size. In recent years, the market of health supplements for seniors has maintained a rapid growth rate, with a CAGR of 13% from 2014 to 2020.



Source: iiMedia Research

2021 China Health Supplement Consumer Age Distributions


China elderly group remain the largest consumption group for health supplement. However, we are seeing consumer age are lowering as more health supplement products are being introduced.



Source: iResearch

China Herbal/Traditional Products Market Continue to Grow


The increasing demand of the China herbal and traditional products may be beneficial to Grape King's product sales.



Source: Euromonitor

Most Favored Health Supplement Among Elderly Chinese

According to iResearch's survey, the core functional requirement of the elderly people is to help regulate the "three highs," despite that Probiotics products are more popular among younger generation, we are seeing elderly demand also picking up.




Source: iResearch



Global Probiotics Market is Still Growing

According to Research and Market, global probiotics market is expecting to reach US\$62 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.6% CAGR between 2016-2022.



Source: Research & Market

Grape King is the 7th Largest Distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.

Rank	Company	Brand	
1	P&G	Align	align
2	SANOFI	Enterogermina	Enterogenmen
3	② 大正製業	Shin Biofermin S	SI SI
7	新語王生技 GRAPE KING BIO	Probiotics & Prebiotics Super 13 Probiotics & Prebiotics	unen-

Source: Euromonitor

^{*}Notes: Global probiotics market includes probiotics supplement, probiotic yoghurt, and sour milk products.



"China Probiotic Market

Probiotics Demand Remains Popular within Young and Middle-Aged Women





Functional needs of young and middle-aged women in purchasing health supplements


	for parents	for themselves	for kids	for partners	
Top 4	immune	vitamins/minerals	immune	immune	
Top 1	enhancement	vitamins/minerals	enhancement	enhancement	
Ton 2	Ton 0		bone health	vitamins/minerals	
Top 2	regulation of 3 highs	enhancement	pone nealth	vitariiiis/minerais	
Top 3	bone health	beauty	probiotics	sleep	
1000	bone nearth	enhancement	probleties	improvement	
Top 4	sleep improvement	sleep improvement	vitamins/minerals	kidney health	
Top 5	vitamins/minerals	probiotics	growth	bone health	
.500	Vitariiiio/iiiiiciais	problettes	improvement	Dolle Health	

Source: iResearch 2021



Taiwan - Grape King Brand Sales Channels









Pro-Partner Overview

4 key numbers of Pro-Partner

- Largest local direct selling company in Taiwan based on revenue.
 - One of the fastest growing direct selling companies in Taiwan (15% sales CAGR from 2008 to 2020)
- Second largest overall direct selling company in Taiwan. (2021 market share: 8%)
- 43 Health and Beauty products for the whole family
- No. 41 in the worldwide direct selling company rankings for 2021

(Source: 2021 DSN Global 100- based on 2020 revenues)




Sales (NT\$)

Bai Yi Jie (toothpaste)



- Grape King's Lactobacillus pentosus GK4
 - → Inhibit 13 kinds of oral bacteria & Prevent cavities
- Xylitol
 - → Anti-plaque
- Sodium fluoride
 - → Prevent enamel erosion
- Mint
 - → Sooth teeth

Hi Spray (oral spray)



→ Inhibit 13 kinds of oral bacteria & Prevent cavities

- Sorbitol
 - → Anti-plaque
- Thyme
 - → Freshen breath
- Mint
 - → Sooth teeth







How is Pro-Partner different from other direct selling companies?





- ✓ No minimum purchase requirement.
- ✓ No inventory pressure. (Members buy products directly from the company)

Products' uniqueness



- ✓ Higher entry barrier for Products (bioresearched and engineered).
- Symbol of national certifications.
- ✓ Products are mostly manufactured inhouse rather than outsourced.

Support



✓ Managed by Grape King, a well-respected health food company in Taiwan, so we can offer dedicated customer service and support. **Training**



- ✓ All the trainings and venues are held by the company, so we can have consistent training quality.
- ✓ All the trainings are free to members.

Compensation




- ✓ Transparent compensation structure.
- ✓ All purchases can be accumulated.
- ✓ All compensation are paid to sales contribution and directly to the members by the company.



Grape King Shanghai Overview

- Established in 1994, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.







*In 2019, the overall demand was impacted by China government' s tightening on direct-selling and healthcare industry & in 2020 the China consumption recovery has been softer-than-expected under the pandemic.




We have identified our R&D focus fitting in the megatrends









Leading to strong growth from our virtual channels





Grape King Taiwan's revenue from virtual channels grew

by **21%** in 1-3Q21 and

accounted ~50%* of total revenue.

*Not including ODM revenue

Growing on Giant's Shoulder



Channels & Distribution Collaboration

- Physical Channels: Taiwan~6,000 stores/ China~ 400 stores/ Southeast Asia ~ 3,000 stores (including convenience stores, pharmacies, department stores)
- Virtual Channels









- **Production Resource Collaboration**
- Taiwan/overseas mutual OEM production

- New adjacencies (such as F&B) expansion
- R&D collaboration, joint product development
- Products agency
- Food safety enhancement

